Trial
NCT01984255
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
—
Condition
Melanoma
Intervention
Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV
Why stopped
standard of care improved combination treatment of ipilimumab plus nivolumab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-29